Download PDF
Aktuelle Dermatologie 2020; 46(08/09): 362-369
DOI: 10.1055/a-1147-4666
Eine Klinik im Blickpunkt

Etablierung des Schwerpunktes Psoriasis an der Universitätshautklinik Rostock und eine praxisbezogene Übersicht über die Biologikatherapie der Psoriasis

Establishment of the Psoriasis Center at the Rostock University Dermatological Clinic and a Practical Overview of the Biological Treatment of Psoriasis
P. Grünwald
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
,
S. Krebs
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
,
P. Troitzsch
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
,
J. Roewer
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
,
S. Emmert
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
,
A. Thiem
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die Diagnostik und Behandlung der Psoriasis stellt einen Schwerpunkt an der Universitätshautklinik Rostock dar. Aufgrund des breiten Spektrums verfügbarer Biologikatherapien für die Behandlung der Psoriasis werden in diesem Artikel praxisbezogene Ratschläge für diese Therapieform gegeben. Dabei wird aufgezeigt, wie das optimale Biologikum für einen individuellen Patienten unter Berücksichtigung möglicher Kontraindikationen, krankheitsspezifischer Aspekte und unerwünschter Wirkungen ausgewählt werden kann. Außerdem wird ein mögliches Vorgehen bei Unterbrechung, Wiederaufnahme oder Umstellung von Biologika erwähnt.

Abstract

The diagnosis and treatment of psoriasis is one of the main topics of the Department of Dermatology at University Medical Center Rostock. Due to the wide spectrum of available biological therapies for psoriasis, this article provides practical guidelines for this form of treatment. Recommendations how to find the optimal agent for an individual patient are given, considering possible contraindications, disease-specific factors and side effects. Furthermore, hints for interruption, resumption and switch of biological therapies are mentioned.



Publication History

Article published online:
20 August 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Augustin M. Versorgung der Psoriasis in Deutschland. 11. Nationale Konferenz zur Versorgung der Psoriasis (05.04.2019). Im Internet (27.04.2020): https://www.psonet.de/2019/10/28/patientenveranstaltung-zum-welt-psoriasistag-2019/
    PubMedGoogle Scholar
  • 2 Nast A, Amelunxen L, Augustin M. et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris – Update 2017. [AWMF-Register Nr. 013/001] 2017
    PubMedGoogle Scholar
  • 3 Mrowietz U, Kragballe K, Reich K. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10 DOI: 10.1007/s00403-010-1080-1.
    CrossrefPubMedGoogle Scholar
  • 4 Augustin M, Krüger K, Radtke MA. et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372 DOI: 10.1159/000119415.
    CrossrefPubMedGoogle Scholar
  • 5 von Kiedrowski R, Dirschka T, Kurzen H. et al. Praxisnaher Behandlungspfad Psoriasis vulgaris. Aktualisierte Empfehlungen für die ambulante Versorgung von Psoriasis-Patienten. Der Deutsche Dermatologe 2016; 5: 1-16
    PubMedGoogle Scholar
  • 6 von Kiedrowski R, Dirschka T, Krähn-Senftleben G. et al. Aktualisierter praxisnaher Behandlungspfad. Empfehlungen für die ambulante Versorgung von Psoriasis vulgaris. Im Internet (30.09.2019): https://www.onkoderm.de/wp-content/uploads/sites/109/2019/09/onkoderm_Behandlungspfad_Psoriasis_2019_E3.pdf
    PubMedGoogle Scholar
  • 7 Menter A, Strober BE, Kaplan DH. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80: 1029-1072 DOI: 10.1016/j.jaad.2018.11.057.
    CrossrefPubMedGoogle Scholar
  • 8 Pariser DM, Bagel J, Gelfand JM. et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143: 239-242 DOI: 10.1001/archderm.143.2.239.
    CrossrefPubMedGoogle Scholar
  • 9 Orbai A-M, Weitz J, Siegel EL. et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 2014; 41: 2290-2294 DOI: 10.3899/jrheum.140878.
    CrossrefPubMedGoogle Scholar
  • 10 Coates LC, Kavanaugh A, Mease PJ. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68: 1060-1071 DOI: 10.1002/art.39573.
    CrossrefPubMedGoogle Scholar
  • 11 Augustin M, Enk A, von Kiedrowski R. et al. Einsatz von Systemtherapeutika und Biologika in der leitliniengerechten Therapie der mittelschweren bis schweren Psoriasis vulgaris. PsoNet Magazin 2017; 4 (Suppl. 01) 1-28
    PubMedGoogle Scholar
  • 12 Elmets CA, Leonardi CL, Davis DMR. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019; 80: 1073-1113 DOI: 10.1016/j.jaad.2018.11.058.
    CrossrefPubMedGoogle Scholar
  • 13 Smith CH, Jabbar-Lopez ZK, Yiu ZZ. et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628-636 DOI: 10.1111/bjd.15665.
    CrossrefPubMedGoogle Scholar
  • 14 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27-40 DOI: 10.1016/j.jaad.2018.06.057.
    CrossrefPubMedGoogle Scholar
  • 15 McInnes IB, Kavanaugh A, Gottlieb AB. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-789 DOI: 10.1016/S0140-6736(13)60594-2.
    CrossrefPubMedGoogle Scholar
  • 16 Deodhar A, Helliwell P, Boencke W. et al. Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study. Arthritis Rheumatol 2019; 71 (Suppl. 10) 805-809
    PubMedGoogle Scholar
  • 17 Mease PJ, Chohan S, Fructuoso FJG. et al. Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol 2019; 71 (Suppl. 10) 78-79 DOI: 10.1136/annrheumdis-2019-eular.8669.
    CrossrefPubMedGoogle Scholar
  • 18 Mease PJ, Kellner H, Morita A. et al. Efficacy and safety of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis 2018; 77: 200-201 DOI: 10.1136/annrheumdis-2018-eular.2140.
    CrossrefPubMedGoogle Scholar
  • 19 Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1 DOI: 10.1002/14651858.CD011535.pub3.
    CrossrefPubMedGoogle Scholar
  • 20 Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170: 261-273 DOI: 10.1111/bjd.12654.
    CrossrefPubMedGoogle Scholar
  • 21 Reich K, Armstrong AW, Foley P. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418-431 DOI: 10.1016/j.jaad.2016.11.042.
    CrossrefPubMedGoogle Scholar
  • 22 Papp KA, Blauvelt A, Bukhalo M. et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med 2017; 376: 1551-1560 DOI: 10.1056/NEJMoa1607017.
    CrossrefPubMedGoogle Scholar
  • 23 Cheuk S, Wikén M, Blomqvist L. et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol 2014; 192: 3111-3120 DOI: 10.4049/jimmunol.1302313.
    CrossrefPubMedGoogle Scholar
  • 24 Mrowietz U, Jong EMGJ de, Kragballe K. et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 438-453 DOI: 10.1111/jdv.12118.
    CrossrefPubMedGoogle Scholar
  • 25 Pasch MC. Nail Psoriasis: A Review of Treatment Options. Drugs 2016; 76: 675-705 DOI: 10.1007/s40265-016-0564-5.
    CrossrefPubMedGoogle Scholar
  • 26 Klaassen KMG, Ploegmakers MJM, van de Kerkhof PCM. et al. Subklinische Enthesitis bei Nagelpsoriasis-Patienten: eine Fall-Kontroll-Studie. J Dtsch Dermatol Ges 2017; 15: 405-413 DOI: 10.1111/ddg.13222_g.
    CrossrefPubMedGoogle Scholar
  • 27 McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage--implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218: 97-102 DOI: 10.1159/000182250.
    CrossrefPubMedGoogle Scholar
  • 28 Tan AL, Benjamin M, Toumi H. et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253-256
    CrossrefPubMedGoogle Scholar
  • 29 Tan AL, Grainger AJ, Tanner SF. et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same?. Arthritis Rheum 2006; 54: 1328-1333
    CrossrefPubMedGoogle Scholar
  • 30 Sanchez IM, Sorenson E, Levin E. et al. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review. Dermatol Ther 2017; 7: 425-446 DOI: 10.1007/s13555-017-0207-0.
    CrossrefPubMedGoogle Scholar
  • 31 Obeid G, Do G, Kirby L. et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2020; 1: CD011628 DOI: 10.1002/14651858.CD011628.pub2.
    CrossrefPubMedGoogle Scholar
  • 32 Kamel J, Routt E. Successful Treatment of Recalcitrant Palmoplantar Pustulosis with Ixekizumab. J Psoriasis Psoriatic Arthritis 2016; 2: 9-10
    CrossrefPubMedGoogle Scholar
  • 33 Mariette X, Förger F, Abraham B. et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77: 228-233 DOI: 10.1136/annrheumdis-2017-212196.
    CrossrefPubMedGoogle Scholar
  • 34 Porter C, Armstrong-Fisher S, Kopotsha T. et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016; 116: 7-12 DOI: 10.1016/j.jri.2016.04.284.
    CrossrefPubMedGoogle Scholar
  • 35 Lockwood SJ, Prens LM, Kimball AB. Adverse Reactions to Biologics in Psoriasis. In: Puig L, Gulliver W. Adverse reactions to biologics. Volume 53. Current problems in dermatology. Basel: S. Karger; 2018: 195-199
    Google Scholar
  • 36 Gottlieb AB, Kalb RE, Langley RG. et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 2014; 13: 1441-1448
    PubMedGoogle Scholar
  • 37 Bonovas S, Minozzi S, Lytras T. et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 2016; 15 (Suppl. 01) 35-54 DOI: 10.1080/14740338.2016.1238458.
    CrossrefPubMedGoogle Scholar
  • 38 Loft ND, Vaengebjerg S, Halling A-S. et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol 2019; DOI: 10.1111/jdv.16073.
    CrossrefPubMedGoogle Scholar
  • 39 Kolios AGA, Yawalkar N, Anliker M. et al. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology 2016; 232: 385-406 DOI: 10.1159/000445681.
    CrossrefPubMedGoogle Scholar
  • 40 Choi YM, Debbaneh M, Weinberg JM. et al. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol 2016; 75: 798-805.e7 DOI: 10.1016/j.jaad.2016.06.014.
    CrossrefPubMedGoogle Scholar
  • 41 Sherman S, Solomon Cohen E, Amitay-Laish I. et al. IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience. Acta Derm Venereol 2019; 99: 769-773 DOI: 10.2340/00015555-3200.
    CrossrefPubMedGoogle Scholar
  • 42 Georgakopoulos JR, Phung M, Ighani A. et al. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol 2019; 33: e7-e8 DOI: 10.1111/jdv.15100.
    CrossrefPubMedGoogle Scholar
  • 43 Costa L, Perricone C, Chimenti MS. et al. Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs R D 2017; 17: 509-522 DOI: 10.1007/s40268-017-0215-7.
    CrossrefPubMedGoogle Scholar
  • 44 Conti A, Peccerillo F, Amerio P. et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol 2019; 180: 1547-1548 DOI: 10.1111/bjd.17580.
    CrossrefPubMedGoogle Scholar